Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.

Panciroli C, Lucente G, Vidal L, Carcereny E, Quiroga V, Pardo JC, Romeo M, Estival A, Manzano JL, Pardo B, Velarde JM, Esteve AM, Lopez D, Mañes A, Tuset V, Villà S, Quintero CB.

Clin Transl Oncol. 2019 May 29. doi: 10.1007/s12094-019-02143-6. [Epub ahead of print]

PMID:
31144211
2.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
3.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, Alcaide J, Gómez A, López R, Manzano JL, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés JI, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Eur J Cancer. 2018 Sep;101:263-272. doi: 10.1016/j.ejca.2018.06.024. Epub 2018 Jul 24.

PMID:
30054049
4.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators.

Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.

PMID:
29794066
5.

Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.

Fernández-Sartorio C, Boada A, Chavez-Bourgeois MM, Ruiz Ares GJ, Arance AM, Manzano JL, García-Herrera A, Carrera C.

Melanoma Res. 2018 Apr;28(2):160-162. doi: 10.1097/CMR.0000000000000422. No abstract available.

PMID:
29485551
6.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.

Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group.

Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.

PMID:
29481492
7.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A.

Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523.

8.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

PMID:
29145602
9.

Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M, Martin-Algarra S; Spanish Melanoma Group (GEM).

Ann Transl Med. 2017 Oct;5(19):389. doi: 10.21037/atm.2017.08.10. Review.

10.

Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study.

Boada A, Tejera-Vaquerizo A, Ribero S, Puig S, Moreno-Ramírez D, Descalzo-Gallego MA, Fierro MT, Quaglino P, Carrera C, Malvehy J, Vidal-Sicart S, Bennássar A, Rull R, Alos L, Requena C, Bolumar I, Traves V, Pla Á, Fernández-Figueras MT, Ferrándiz C, Pascual I, Manzano JL, Sánchez-Lucas M, Giménez-Xavier P, Ferrandiz L, Nagore E.

Int J Cancer. 2018 Feb 1;142(3):641-648. doi: 10.1002/ijc.31078. Epub 2017 Oct 13.

11.

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).

Capdevila J, Trigo JM, Aller J, Manzano JL, Adrián SG, Llopis CZ, Reig Ò, Bohn U, Cajal TRY, Duran-Poveda M, Astorga BG, López-Alfonso A, Martínez JM, Porras I, Reina JJ, Palacios N, Grande E, Cillán E, Matos I, Grau JJ.

Eur J Endocrinol. 2017 Oct;177(4):309-317. doi: 10.1530/EJE-17-0243. Epub 2017 Jul 7.

PMID:
28687563
12.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19.

13.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

14.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S; Spanish Melanoma Group.

Clin Transl Oncol. 2017 Jun;19(6):761-768. doi: 10.1007/s12094-016-1602-1. Epub 2017 Jan 4.

PMID:
28054320
15.

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).

Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL.

Clin Transl Oncol. 2016 Dec;18(12):1172-1178. doi: 10.1007/s12094-016-1586-x. Epub 2016 Nov 28.

16.

Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.

Feliu J, Díez de Corcuera I, Manzano JL, Valladares-Ayerbes M, Alcaide J, García García T, Vera R, Sastre J.

Clin Transl Oncol. 2017 Apr;19(4):498-507. doi: 10.1007/s12094-016-1556-3. Epub 2016 Oct 7.

PMID:
27718155
17.

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer.

Martínez-Cardús A, Moran S, Musulen E, Moutinho C, Manzano JL, Martinez-Balibrea E, Tierno M, Élez E, Landolfi S, Lorden P, Arribas C, Müller F, Bock C, Tabernero J, Esteller M.

Gastroenterology. 2016 Nov;151(5):961-972. doi: 10.1053/j.gastro.2016.08.001. Epub 2016 Aug 10.

18.

Resistant mechanisms to BRAF inhibitors in melanoma.

Manzano JL, Layos L, Bugés C, de Los Llanos Gil M, Vila L, Martínez-Balibrea E, Martínez-Cardús A.

Ann Transl Med. 2016 Jun;4(12):237. doi: 10.21037/atm.2016.06.07. Review.

19.

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.

Ruiz de Porras V, Bystrup S, Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L, James MI, Iwuji C, Manzano JL, Layos L, Bugés C, Abad A, Martínez-Balibrea E.

Sci Rep. 2016 Apr 19;6:24675. doi: 10.1038/srep24675.

20.

Erratum to: SEOM guidelines for the treatment of gastric cancer 2015.

Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A.

Clin Transl Oncol. 2016 Apr;18(4):426. doi: 10.1007/s12094-016-1491-3. No abstract available.

21.

Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.

Martín-Algarra S, de la Cruz-Merino L, Soriano V, Manzano JL, Espinosa E.

Clin Transl Oncol. 2016 Oct;18(10):1044-50. doi: 10.1007/s12094-016-1484-2. Epub 2016 Jan 22.

PMID:
26801342
22.

Seom guidelines for the treatment of gastric cancer 2015.

Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A.

Clin Transl Oncol. 2015 Dec;17(12):996-1004. doi: 10.1007/s12094-015-1456-y. Epub 2015 Dec 21. Erratum in: Clin Transl Oncol. 2016 Apr;18(4):426.

23.

Appendiceal mixed adenoneuroendocrine carcinomas, a rare entity that can present as a Krukenberg tumor: case report and review of the literature.

Romeo M, Quer A, Tarrats A, Molina C, Radua J, Manzano JL.

World J Surg Oncol. 2015 Nov 26;13:325. doi: 10.1186/s12957-015-0740-1. Review.

24.

Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance.

Martinez-Cardús A, Vizoso M, Moran S, Manzano JL.

Ann Transl Med. 2015 Sep;3(15):209. doi: 10.3978/j.issn.2305-5839.2015.06.20. Review.

25.

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R.

Melanoma Res. 2015 Dec;25(6):486-95. doi: 10.1097/CMR.0000000000000187.

PMID:
26366702
26.

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.

Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M, Abad A.

Mol Cancer Ther. 2015 Aug;14(8):1767-76. doi: 10.1158/1535-7163.MCT-14-0636. Epub 2015 Jul 16. Review.

27.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P.

BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6.

28.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

29.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

Sastre J, Massuti B, Pulido G, Guillén-Ponce C, Benavides M, Manzano JL, Reboredo M, Rivera F, Grávalos C, Safont MJ, Martínez Villacampa M, Llovet P, Dotor E, Díaz-Rubio E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours TTD.

Eur J Cancer. 2015 Jul;51(11):1371-80. doi: 10.1016/j.ejca.2015.04.013. Epub 2015 May 8.

PMID:
25963019
30.

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.

Ginés A, Bystrup S, Ruiz de Porras V, Guardia C, Musulén E, Martínez-Cardús A, Manzano JL, Layos L, Abad A, Martínez-Balibrea E.

PLoS One. 2015 May 8;10(5):e0123830. doi: 10.1371/journal.pone.0123830. eCollection 2015.

31.

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Grávalos C, Biondo S, Palacios A, Aranda E.

BMC Cancer. 2015 Feb 26;15:60. doi: 10.1186/s12885-015-1053-z.

32.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG.

Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.

33.

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, Alsina M, Yuste Izquierdo AL, López C, Díaz-Rubio E, Conde V, Reboredo M, Cano MT, Pachón V, Aranda E.

Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.

PMID:
25491381
34.

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.

Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González E, Grávalos C, Constenla M, Manzano JL, Losa F, Maurel J, Dueñas R, Massuti B, Gallego J, Aparicio J, Antón A, Aranda E.

Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29.

PMID:
23359181
35.

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12.

36.

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

Sastre J, Grávalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, Manzano JL, Benavides M, Hidalgo M, Díaz-Rubio E, Aranda E.

Oncologist. 2012;17(3):339-45. doi: 10.1634/theoncologist.2011-0406. Epub 2012 Feb 23.

37.

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Díaz-Rubio E.

Ann Oncol. 2012 Jul;23(7):1919-25. doi: 10.1093/annonc/mdr560. Epub 2011 Dec 9.

PMID:
22156621
38.

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.

Grávalos C, García-Alfonso P, Afonso R, Arrazubi V, Arrivi A, Cámara JC, Capdevila J, Gómez-España A, Lacasta A, Manzano JL, Salgado M, Sastre J, Díaz-Rubio E.

Clin Transl Oncol. 2011 Dec;13(12):862-8. doi: 10.1007/s12094-011-0747-1. Review.

PMID:
22126729
39.

Platinum complexes for multi-parametric assays using microarray systems.

González M, Bartolomé R, Matarraz S, Rodríguez-Fernández E, Manzano JL, Pérez-Andrés M, Orfao A, Fuentes M, Criado JJ.

J Inorg Biochem. 2012 Jan;106(1):43-5. doi: 10.1016/j.jinorgbio.2011.08.015. Epub 2011 Aug 28.

PMID:
22112838
40.

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V.

Br J Cancer. 2010 Aug 10;103(4):581-9. doi: 10.1038/sj.bjc.6605776. Epub 2010 Jul 13.

41.

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).

Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M.

Crit Rev Oncol Hematol. 2011 Jan;77(1):78-84. doi: 10.1016/j.critrevonc.2009.11.005. Epub 2009 Dec 29.

PMID:
20042346
42.

Fluorescent cisplatin analogues and cytotoxic activity.

Rodríguez-Fernández E, Manzano JL, Alonso A, Almendral MJ, Pérez-Andrés M, Orfao A, Criado JJ.

Curr Med Chem. 2009;16(32):4314-27. Review.

PMID:
19754416
43.

A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines.

Martinez-Balibrea E, Plasencia C, Ginés A, Martinez-Cardús A, Musulén E, Aguilera R, Manzano JL, Neamati N, Abad A.

Mol Cancer Ther. 2009 Apr;8(4):771-8. doi: 10.1158/1535-7163.MCT-08-0882.

44.

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.

Martinez-Balibrea E, Martínez-Cardús A, Musulén E, Ginés A, Manzano JL, Aranda E, Plasencia C, Neamati N, Abad A.

Int J Cancer. 2009 Jun 15;124(12):2905-10. doi: 10.1002/ijc.24273.

45.

Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.

Martín-Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, Plazaola A, Tanovic A, Paz-Ares L.

Eur J Cancer. 2009 Mar;45(5):732-5. doi: 10.1016/j.ejca.2008.12.005. Epub 2009 Jan 29.

PMID:
19186051
46.

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.

Martinez-Cardús A, Martinez-Balibrea E, Bandrés E, Malumbres R, Ginés A, Manzano JL, Taron M, Garcia-Foncillas J, Abad A.

Mol Cancer Ther. 2009 Jan;8(1):194-202. doi: 10.1158/1535-7163.MCT-08-0659.

47.

Bisursodeoxycholate(ethylenediamine)platinum(II): a new autofluorescent compound. Cytotoxic activity and cell cycle analysis in ovarian and hematological cell lines.

Pérez-Andrés M, Benito JJ, Rodríguez-Fernández E, Corradetti B, Primo D, Manzano JL, Orfao A, Criado JJ.

Dalton Trans. 2008 Nov 28;(44):6159-64. doi: 10.1039/b807965j. Epub 2008 Sep 25.

PMID:
18985248
48.

Reflections on adjuvant treatment of gastric cancer.

Abad A, Manzano JL, Martí C.

Ther Clin Risk Manag. 2007 Aug;3(4):563-7.

49.

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.

Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of Digestive Tumours.

Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025. Epub 2008 Apr 28.

PMID:
18448328
50.

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.

Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, Gallego R, Casado E, Manzano JL, Carcereny E, Guix M, Fernández-Llamazares J, Rosell R.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1075-83. doi: 10.1007/s00280-008-0700-3. Epub 2008 Mar 12.

PMID:
18335219

Supplemental Content

Loading ...
Support Center